DISC MEDICINE INC (IRON)
Health Care · Biotechnology · NASDAQ
Disc Medicine is a clinical-stage biopharmaceutical firm advancing a pipeline of novel therapies to treat serious hematologic and red blood cell disorders by targeting heme biosynthesis and iron homeostasis.
What DISC MEDICINE INC does
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases. Its pipeline targets heme biosynthesis and iron homeostasis, with a primary focus on treating erythropoietic porphyrias (EPP and XLP) and various forms of anemia. The company utilizes validated molecular mechanisms to develop novel treatments for red blood cell disorders.
Themes: hematology, porphyria treatment, anemia therapy, red blood cell disorders, heme biosynthesis pathway, iron homeostasis
Fundamentals
- Price$79.81 as of 2026-08-21 close
- Market cap$3.1B as of 2026-08-21
- 1-year return+33.6% 2025-08-21 close $59.75 → 2026-08-21 close $79.81
- P/En/a earnings data not available
- ROE-37.2% as of 2026-08-24
- Debt / equity0.09 as of 2026-08-24
- Beta0.90 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How IRON compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IRON is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
60.6 #184 of 1,704 scored · #43 of 240 in Health Care
Catalysts 69th: open-market insider buys in 90 days 19, analysts have raised their average price target by 0.4% since the prior reading; momentum 60th: its RSI momentum gauge is in neutral territory; weakest is trend 57th: a "golden cross" — its 50-day average is above its 200-day.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How DISC MEDICINE INC looks technically
DISC MEDICINE INC (IRON) is trading 6.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. It is 19.8% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 6.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $75.62 | $75.62 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $74.83 | $74.83 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 83.119. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 6.7% above | +6.7% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($74.46 to $83.12) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 61.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $99.50 | $99.50 |
|---|---|---|
| From the 52-week high | it is 19.8% below its 52-week high (its highest price of the past year) | -19.8% |
| Above the 52-week low | it is 99.5% above its 52-week low (its lowest price of the past year) | +99.5% |
| Below the 52-week high | it is 19.8% below its highest point of the past year | 19.8% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $572.55 (set on 2021-03-15) | $572.55 |
| Given back of the 52-week move | over the past year its closes ranged ($55.95 to $94.11), and it has recovered close to two thirds of its fall from last year’s high — 63% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $79.53 to $80.75. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.5% |
| From the all-time high | it is 86.1% below its all-time high | -86.1% |
| Nearest price level | it is trading 3.1% below a resistance level at $82.31 — a price it turned at five times since 2025-11-11, most recently on 2026-08-12. Since 2024-08-21 it has 14 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.1% |
| All-time low | its lowest closing price on record is $15.00 (set on 2022-12-30) | $15.00 |
| Above the all-time low | it is 432.1% above its all-time low | +432.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.03 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $74.08 and $82.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $74.08 – $78.26 – $82.44 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (6.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.4% since the prior reading | +0.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 49 sessions ago and has not traded back through the level it left behind at 65.8 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.3 percentage points (the stock gained 5.6% while the market gained 2.3%) | +3.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 15.8 percentage points (the stock gained 18.9% while the market gained 3.1%) | +15.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.0 percentage points (the stock gained 30.1% while the market gained 11.1%) | +19.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 13.1 percentage points (the stock gained 33.6% while the market gained 20.5%) | +13.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.0% of the share price. | +5.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $69.58 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +14.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $78.97 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +1.1% |
Price levels it has turned at before
IRON last closed at $79.81 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $82.31 | Resistance | 3.1% above the last close | turned there five times · 2025-11-11 to 2026-08-12 |
| $72.12 | Support | 9.6% below the last close | turned there five times · 2025-12-19 to 2026-07-28 |
| $90.09 | Resistance | 12.9% above the last close | turned there twice · 2025-10-28 to 2025-11-06 |
| $68.76 | Support | 13.8% below the last close | turned there five times · 2024-11-11 to 2026-02-25 |
| $64.93 | Support | 18.6% below the last close | turned there four times · 2025-08-18 to 2026-06-08 |
| $96.53 | Resistance | 20.9% above the last close | turned there twice · 2025-10-17 to 2025-11-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $83.12.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$101.58 range $79.00 – $128.00; median $100.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IRON
- Consensus EPS estimate-$1.74 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure, particularly the Phase 3 APOLLO trial, poses a significant risk to the company's future.","The company has received a complete response letter (CRL) from the FDA for its lead candidate, creating regulatory uncertainty for approval.","Significant reliance on a limited number of product candidates for future revenue potential."]
What changed in the latest 10-Q
AI-assisted comparison of IRON's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05): FDA issued a complete response letter (CRL) in February 2026 regarding bitopertin NDA
- Newer filing (2026-05-05): FDA concluded trials did not show evidence of association between PPIX percent change and sunlight exposure-based endpoints
- Newer filing (2026-05-05): FDA determined uncertainty regarding whether bitopertin's effect on PPIX is reasonably likely to predict clinical benefit
- Newer filing (2026-05-05): Company scheduled Type A meeting with FDA during second quarter of 2026 to review approach for resubmitting NDA
- Newer filing (2026-05-05): APOLLO enrollment completed in first quarter of 2026 with n=183
- Newer filing (2026-05-05): Topline data from APOLLO expected in fourth quarter of 2026
- Newer filing (2026-05-05): FDA decision on NDA anticipated by mid-2027
- Newer filing (2026-05-05): RALLY-MF reported initial data in December 2025 with meaningful overall anemia responses
- Newer filing (2026-05-05): Updated data from RALLY-MF expected in June 2026
- Removed:
- Older filing (2025-11-06): Bitopertin indicated for treatment of Diamond-Blackfan Anemia (DBA) in overview section
- Older filing (2025-11-06): DISC-0974 indicated for treatment of anemia of chronic kidney disease (CKD) in overview section
- Older filing (2025-11-06): Company planning to accelerate activities to support US approval and launch of bitopertin in late 2025 or early 2026
- Older filing (2025-11-06): Details on CNPV benefits including enhanced communications and rolling review with one to two months review time
- Older filing (2025-11-06): Collaborative research and development agreement with National Institutes of Health (NIH) for bitopertin clinical trial in DBA begun in July 2023
- Older filing (2025-11-06): Older filing stated demonstrating 'a clear association between PPIX reduction and clinical endpoints' in BEACON and AURORA trials
- Older filing (2025-11-06): Reference to Phase 1b/2 clinical trial initiated in February 2023 in patients with non-dialysis dependent CKD and anemia
- Older filing (2025-11-06): References to interim data presentations from CKD trial in October 2024
- Older filing (2025-11-06): Statement that topline data from RALLY-MF expected at American Society of Hematology Annual Meeting in December 2025
- Reworded:
- Newer filing (2026-05-05) changed reference period: 'audited consolidated financial statements...for the year ended December 31, 2025' vs older filing reference to 'December 31, 2024'
- Newer filing (2026-05-05): Condensed description of bitopertin development history, removing specific dates of presentations and detailed timeline of BEACON/AURORA data presentations
- Newer filing (2026-05-05): Changed from 'All participants who complete AURORA or BEACON' to 'All participants in AURORA and BEACON'
- Newer filing (2026-05-05): HELIOS data changed from 'improved liver biomarkers' to 'improvements in...liver biomarkers'
- Newer filing (2026-05-05): Removed specific language about 'rolling review' and '1-2 months' review time associated with CNPV
- Newer filing (2026-05-05): Changed 'clinical trial' to 'trial' and removed reference to registrational trial details being in separate paragraph
- Newer filing (2026-05-05): DISC-0974 section text appears truncated at 'If po'
- Notes:
- Newer filing text appears incomplete/truncated at the end of the DISC-0974 section ('If po'), limiting full comparison of that section
- Older filing text also appears truncated but at different point ('anem'), suggesting both are partial excerpts
Risk Factors
- Added:
- Newer filing (2026-05-05) removed phrase 'early-stage' before 'clinical trials' in the inception description
- Removed:
- Older filing (2025-11-06) included phrase 'including as a result of public health crises' after 'changing and volatile U.S. and global economic environments'
- Reworded:
- Net loss figures updated: newer filing (2026-05-05) reports '$63.5 million and $34.1 million for the three months ended March 31, 2026 and 2025' versus older filing (2025-11-06) which reported '$151.7 million and $79.9 million for the nine months ended September 30, 2025 and 2024'
- Accumulated deficit updated: newer filing (2026-05-05) shows '$573.7 million as of March 31, 2026' versus older filing (2025-11-06) which showed '$449.7 million as of September 30, 2025'
- Research and development expense language changed from 'increase significantly' (2025-11-06) to 'continue to increase significantly' (2026-05-05)
- Page number changed from '31' in older filing to '28' in newer filing
- Notes:
- Both filings appear truncated at the end of the 'We have no products approved for commercial sale' section, making full comparison of that section not assessable
- The different reporting periods (three months ended March 31 vs. nine months ended September 30) and different fiscal year ends make the numerical comparisons reflect different time periods rather than comparable periods
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 17 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($400000) — 1 selling insider
- Last 90 days0 buys · 17 sells ($8M) — 3 selling insiders
- Last 180 days0 buys · 21 sells ($9M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IRON's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IRON as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,721,919
- Reported value $621,619,502
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IRON had 7,394,606 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IRON had 19.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.92 days to cover at the same settlement.
- Reported short interest (shares) 7,394,606
- Short interest (% of shares outstanding) 19.3%
- Prior settlement (shares) 7,290,442
- Reported change 1.43%
- Days to cover (reported) 20.92
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Ironwood Pharmaceuticals (IRWD)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- GlaxoSmithKline (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IRON vs…
Frequently asked questions
What does DISC MEDICINE INC (IRON) do?
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases. Its pipeline targets heme biosynthesis and iron homeostasis, with a primary focus on treating erythropoietic porphyrias (EPP and XLP) and various forms of anemia. The company utilizes validated molecular mechanisms to develop novel treatments for red blood cell disorders.
What sector is DISC MEDICINE INC (IRON) in?
DISC MEDICINE INC (IRON) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are DISC MEDICINE INC's (IRON) competitors?
Notable peers of DISC MEDICINE INC (IRON) include Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, Amgen, Bristol Myers Squibb and GlaxoSmithKline. This peer set is informational only — not financial advice.
Is DISC MEDICINE INC (IRON) overbought or oversold right now?
DISC MEDICINE INC (IRON) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IRON come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.